针对晚期非小细胞肺癌中的MET通路的靶向治疗引起了特别的关注，因其作为原发性致癌驱动因子和获得性耐药的次要致癌驱动因子的作用。MET通路的激活可以通过多种机制发生，这可能会使诊断和治疗方法变得复杂。近年来，已经开发出一些有希望的MET定向疗法。在本叙述性综述中，我们总结了MET作为临床相关的驱动突变的生物学和机制、不同的MET改变包括诊断挑战、在获得性耐药的情况下的重要性以及晚期非小细胞肺癌中的新型治疗策略。Copyright © 2023 Elsevier B.V. 版权所有。

Targeting the MET pathway in advanced NSCLC has been of particular interest due to its role as both a primary oncogenic driver and secondary oncogenic driver of acquired resistance. Activation of the MET pathway can occur through several mechanisms, which can complicate the diagnostic and treatment approach. Recently, several MET-directed therapies have been developed with promising results. In this narrative review, we summarize the biology and mechanism of MET as a clinically relevant driver mutation, distinct MET alterations including diagnostic challenges, significance in the setting of acquired resistance, and novel treatment strategies in advanced NSCLC.Copyright © 2023 Elsevier B.V. All rights reserved.